$OTLC
Oncotelic Therapeutics, Inc.

2016 Q4 Form 10-Q Financial Statement

#000119312516766839 Filed on November 14, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2015 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.140M $1.190M $1.140M
YoY Change 14.0% 4.39% -5.79%
% of Gross Profit
Research & Development $2.340M $2.075M $2.457M
YoY Change -21.48% -15.55% 9.69%
% of Gross Profit
Depreciation & Amortization $0.00 $10.00K $10.00K
YoY Change 0.0% -50.0%
% of Gross Profit
Operating Expenses $3.480M $3.262M $3.599M
YoY Change -12.56% -9.36% 4.23%
Operating Profit -$3.262M -$3.599M
YoY Change -9.36% 4.23%
Interest Expense $20.00K $30.00K $10.00K
YoY Change 100.0% 200.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $0.00
YoY Change -100.0%
Pretax Income -$3.450M -$3.240M -$3.590M
YoY Change -13.1% -9.75% 4.06%
Income Tax
% Of Pretax Income
Net Earnings -$3.450M -$3.236M -$3.592M
YoY Change -13.1% -9.91% 4.12%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.13 -$0.12 -$0.14
COMMON SHARES
Basic Shares Outstanding 26.54M shares 26.54M shares 26.54M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2016 Q3 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.05M $16.28M $30.25M
YoY Change -55.84% -46.18% -8.03%
Cash & Equivalents $3.535M $5.167M $30.25M
Short-Term Investments $8.510M $11.11M
Other Short-Term Assets $2.020M $930.0K $420.0K
YoY Change 1736.36% 121.43% 41900.0%
Inventory
Prepaid Expenses $1.946M
Receivables
Other Receivables
Total Short-Term Assets $14.07M $17.21M $30.67M
YoY Change -48.63% -43.87% -7.54%
LONG-TERM ASSETS
Property, Plant & Equipment $11.00K $14.00K $36.00K
YoY Change -63.33% -61.11% 20.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $33.00K $33.00K $33.00K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $44.00K $47.00K $69.00K
YoY Change -30.16% -31.88% -19.77%
TOTAL ASSETS
Total Short-Term Assets $14.07M $17.21M $30.67M
Total Long-Term Assets $44.00K $47.00K $69.00K
Total Assets $14.11M $17.26M $30.74M
YoY Change -48.59% -43.84% -7.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $310.0K $532.0K $317.0K
YoY Change 8.01% 67.82% -13.15%
Accrued Expenses $1.300M $950.0K $1.380M
YoY Change -28.57% -31.16% 5.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.614M $1.485M $1.698M
YoY Change -23.25% -12.54% 1.43%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.614M $1.485M $1.698M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.610M $1.490M $1.700M
YoY Change -23.33% -12.35% 1.8%
SHAREHOLDERS EQUITY
Retained Earnings -$278.5M -$275.0M -$260.8M
YoY Change 5.16% 5.43% 4.96%
Common Stock $291.0M $290.8M $289.9M
YoY Change 0.28% 0.31% 3.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.50M $15.78M $29.04M
YoY Change
Total Liabilities & Shareholders Equity $14.11M $17.26M $30.74M
YoY Change -48.59% -43.84% -7.57%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2015 Q3
OPERATING ACTIVITIES
Net Income -$3.450M -$3.236M -$3.592M
YoY Change -13.1% -9.91% 4.12%
Depreciation, Depletion And Amortization $0.00 $10.00K $10.00K
YoY Change 0.0% -50.0%
Cash From Operating Activities -$4.230M -$3.070M -$2.840M
YoY Change 42.42% 8.1% -15.98%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$10.00K
YoY Change -200.0%
Acquisitions
YoY Change
Other Investing Activities $2.600M $290.0K
YoY Change
Cash From Investing Activities $2.600M $290.0K $10.00K
YoY Change 2800.0% -200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -4.230M -3.070M -2.840M
Cash From Investing Activities 2.600M 290.0K 10.00K
Cash From Financing Activities 0.000 0.000 0.000
Net Change In Cash -1.630M -2.780M -2.830M
YoY Change -45.3% -1.77% -16.52%
FREE CASH FLOW
Cash From Operating Activities -$4.230M -$3.070M -$2.840M
Capital Expenditures $0.00 -$10.00K
Free Cash Flow -$4.230M -$2.830M
YoY Change 42.42% -16.52%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26544934 shares
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30251000
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2016Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26545000 shares
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26545000 shares
CY2016Q3 us-gaap Assets
Assets
17261000
CY2016Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2016Q3 us-gaap Assets Current
AssetsCurrent
17214000
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000 shares
CY2016Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
290521000
CY2016Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
16280000
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5167000
CY2016Q3 us-gaap Common Stock Value
CommonStockValue
265000
CY2016Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
532000
CY2016Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9842000 shares
CY2016Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
497000
CY2016Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
16280000
CY2016Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2016Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2016Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17261000
CY2016Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1485000
CY2016Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
410000
CY2016Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33000
CY2016Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2016Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14000
CY2016Q3 us-gaap Short Term Investments
ShortTermInvestments
11113000
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
15776000
CY2016Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1300000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.54
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0
CY2016Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-275010000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
677000 shares
CY2016Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
934000
CY2016Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.29
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
3006000 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3048000 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.40
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4049000 shares
CY2016Q3 matn Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber
1043000 shares
CY2016Q3 matn Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
46000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30031000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26545000 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26545000 shares
CY2015Q4 us-gaap Assets
Assets
27453000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
27390000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000 shares
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
289894000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27285000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
265000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24748000 shares
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
287000
CY2015Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9842000 shares
CY2015Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
636000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27453000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2103000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
262000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
25350000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.01
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-264809000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2695000 shares
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
105000
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2031000 shares
CY2015Q4 matn Accrued Clinical Trial Expenses
AccruedClinicalTrialExpenses
918000
CY2016Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
220000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3597000
us-gaap Depreciation
Depreciation
15000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
us-gaap Operating Expenses
OperatingExpenses
9704000
us-gaap Net Income Loss
NetIncomeLoss
-9688000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-14000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
94000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9704000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
9195000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
279000
us-gaap Investment Income Interest
InvestmentIncomeInterest
15000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8961000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9195000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6107000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.92 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.017 pure
us-gaap Share Based Compensation
ShareBasedCompensation
527000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
dei Entity Registrant Name
EntityRegistrantName
MATEON THERAPEUTICS INC
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000908259
dei Document Period End Date
DocumentPeriodEndDate
2016-09-30
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-22118000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3855000
us-gaap Depreciation
Depreciation
16000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
us-gaap Operating Expenses
OperatingExpenses
10284000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
7802000
us-gaap Net Income Loss
NetIncomeLoss
-10201000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-11113000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
829000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10284000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
18915000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-618000
us-gaap Investment Income Interest
InvestmentIncomeInterest
84000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-11005000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with U.S.&#xA0;generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y5M9D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.72
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.14
dei Trading Symbol
TradingSymbol
MATN
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6429000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.89 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2238000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.015 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
220000 shares
us-gaap Share Based Compensation
ShareBasedCompensation
627000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3262000
CY2016Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
26000
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2075000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26545000 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y1M24D
matn Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted
2238000 shares
matn Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeited
-220000 shares
matn Number Of Drug Candidates
NumberOfDrugCandidates
2 Candidate
matn Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term Two
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo
P8Y4M10D
matn Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm
P6Y10M13D
matn Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice
2.26
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1142000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
3599000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-3592000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3599000
CY2015Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
7000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2457000
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26545000 shares
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1187000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
3262000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-3236000
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26545000 shares

Files In Submission

Name View Source Status
0001193125-16-766839-index-headers.html Edgar Link pending
0001193125-16-766839-index.html Edgar Link pending
0001193125-16-766839.txt Edgar Link pending
0001193125-16-766839-xbrl.zip Edgar Link pending
d96486d10q.htm Edgar Link pending
d96486dex311.htm Edgar Link pending
d96486dex312.htm Edgar Link pending
d96486dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
matn-20160930.xml Edgar Link completed
matn-20160930.xsd Edgar Link pending
matn-20160930_cal.xml Edgar Link unprocessable
matn-20160930_def.xml Edgar Link unprocessable
matn-20160930_lab.xml Edgar Link unprocessable
matn-20160930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending